Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Actinium Pharmaceuticals (ATNM) Equity Average (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Equity Average for 6 consecutive years, with $41.0 million as the latest value for Q3 2024.

  • On a quarterly basis, Equity Average fell 15.12% to $41.0 million in Q3 2024 year-over-year; TTM through Sep 2024 was $41.0 million, a 15.12% decrease, with the full-year FY2023 number at $51.4 million, down 26.54% from a year prior.
  • Equity Average was $41.0 million for Q3 2024 at Actinium Pharmaceuticals, down from $43.8 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $80.4 million in Q3 2021 to a low of $40.0 million in Q4 2023.
  • A 4-year average of $60.8 million and a median of $65.4 million in 2022 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: fell 2.79% in 2022, then plummeted 41.95% in 2023.
  • Actinium Pharmaceuticals' Equity Average stood at $76.9 million in 2021, then fell by 10.46% to $68.9 million in 2022, then tumbled by 41.95% to $40.0 million in 2023, then increased by 2.6% to $41.0 million in 2024.
  • Per Business Quant, the three most recent readings for ATNM's Equity Average are $41.0 million (Q3 2024), $43.8 million (Q2 2024), and $40.1 million (Q1 2024).